NAFDAC shuts six pharmaceutical manufacturers for non-compliance

health

NAFDAC shuts six pharmaceutical manufacturers for non-compliance

National Agency for Food, Drug Administration and Control (NAFDAC) has shut down six pharmaceutical manufacturers for non-compliance with Good Manufacturing Practice (GMP).

NAFDAC
NAFDAC DG Prof. Mojisola Adeyeye

Prof. Mojisola Adeyeye, director general of the Agency, said this in a statement by Mr Sayo Akintola, Resident Media Consultant, NAFDAC, and made available to the media on Monday, in Abuja.

NAFDAC did not name the companies, neither did it name the states where they operated from.

Adeyeye said that the action of NAFDAC was in accordance with its zero tolerance for circulation of substandard and falsified medicines in the country.

“The Pharmaceutical companies were shut down following a nationwide surveillance on their manufacturing activities.

“These local manufacturers, in spite of appropriate notification failed to meet minimum Good Manufacturing Practice (GMP) standards in line with extant requirements to assure the quality, safety and efficacy of Pharmaceutical products,” she said.

She expressed dissatisfaction with the affected manufacturers for their failure to meet up with even the minimum GMP, in spite of the notifications given to them.

The Director General, who reiterated the determination of her agency to end the circulation of substandard and falsified medicines in Nigeria, said that such unpatriotic activities were uncovered following a nationwide surveillance exercise.

Adeyeye explained that the punitive measure meted out to the companies would serve as deterrent to others, both local and foreign, that failed to comply with GMP requirements, saying that the defaulting companies would remain closed until they complied.

According to her, a foreign manufacturer of Finished Pharmaceutical Products (FPPs) was recently blacklisted and their local representative delisted for gross violation of NAFDAC’s extant laws and regulations.

Adeyeye reaffirmed NAFDAC’s commitment to safeguard public health and its relentless efforts in ensuring that only medicines that were safe, efficacious and of good quality were accessible to the country’s population. (NAN)